Fly News Breaks for November 13, 2019
Nov 13, 2019 | 17:02 EDT
Roth Capital analyst Zegbeh Jallah resumed coverage of GlycoMimetics with a Buy rating and $12 price target. The analyst notes that the stock fell after the August announcement that GMI-1070 for Sickle-cell did not meet its Phase 3 primary endpoint. Now that volatility has "come out of the stock", Jallah is positive on the company's "remaining robust pipeline" and recommends that investors reconsider buying shares going into its ASH updates in December, which she expects will build momentum.
News For GLYC From the Last 2 Days
There are no results for your query GLYC